Advancing Polymers for Solubility Enhancement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advancing Polymers for Solubility Enhancement
Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.


Pharmaceutical Technology
pp. s6-s11

Quality by design

PharmTech: Quality by design (QbD) is an overarching consideration in drug development. With respect to solubility enhancement, what are the critical quality attributes and/or critical process parameters important in excipient selection?

Morgen (Bend Research): Recently, pharmaceutical companies, excipient providers, and CRDMOs (contract research/development/manufacturing organizations) have launched significant initiatives to bring QbD principles to the selection and design of the polymer, the formulation, and the process space. With respect to the polymer, critical quality attributes might include molecular-weight distribution and chemistry attributes, such as the ratio and sequence of different monomeric units and/or the number and substitution pattern of hydrophobic groups on the polymer backbone. There are instances in which relatively small differences in chemistry can significantly affect the performance of the polymer and the formulation. In some cases, the impurity profile of the polymer can also be critical to the performance.

Typically, a number of critical parameters on the process side will influence the choice of excipients. Depending on the process, solvents, and solution temperatures may be selected based on solubility of API or its compatibility with the solvent, which can in turn influence the choice of the polymer. Likewise, process- time–temperature profiles can be critical process parameters, particularly for the choice of HME excipients, to ensure adequate mixing for complete dispersal and dissolution of the API into the heated polymer matrix if a solid solution is desired.

Koblinski (Dow): Selecting the right excipient with control of the critical quality attributes is crucial to a robust formulation. A QbD approach to drug development helps the final drug product to have the desired therapeutic effect on a consistent basis. In solubility enhancement, excipients play the role of stabilizing the drug and keeping it in the desired state to achieve the maximum drug release and concentration sustainment. A QbD study with an excipient, for example HPMCAS, will look at characteristics of the polymer, such as acetyl and succinyl substitution using a design of experiment study to cover the experimental space to find the enhanced substitution levels for solubilization of the specific drug. Through studies done at Dow, we have found some drugs, such as phenytoin, are very sensitive to changes in polymer substitution levels and, therefore, require tight control around the enhanced values for consistent performance. Other less sensitive drugs can tolerate a wider range of substitution values while maintaining performance. A QbD program, in cooperation with the excipient manufacturer, can help formulators develop a robust and therapeutically efficient drug product.

Asgarzadeh (Evonik): When selecting excipients for solubility enhancement, excipient physicochemical properties such as morphological characteristics, aqueous/pH solubility, molecular weight, crystalline structure, porosity, density, and viscosity are amongst the critical quality attributes (CQAs) that should be evaluated. The impact of selected CQAs based upon the risk-assessment survey on the properties of the final product should be studied and well understood. Excipients in a solubility-enhanced formulation should not be considered as fillers or part of the binding matrix anymore because they contribute to the performance of API that otherwise does not have any absorption and bioavailability. The critical process parameters (CPPs) are process specific attributes. For solubility-enhancement applications, melt extrusion and spray drying are the most commonly used technologies. The CPPs for melt extrusion are the screw speed, extrusion temperature, feed rate, glass-transition temperature of the drug-polymer mixture, and melt viscosity. For spray drying however, parameters such as spray rate, percent solids content, size, and scale of the spray dryer, nozzle size and temperature in the expansion chamber should be considered.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here